PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature

Jian Xiao; Cheng-Ping Hu; Bi-Xiu He; Xi Chen; Xiao-Xiao Lu; Ming-Xuan Xie; Wei Li; Shu-Ya He; Shao-Jin You; Qiong Chen

doi:10.18632/oncotarget.11068

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature

Jian Xiao, Cheng-Ping Hu, Bi-Xiu He, Xi Chen, Xiao-Xiao Lu, Ming-Xuan Xie, Wei Li, Shu-Ya He, Shao-Jin You and Qiong Chen _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:57832-57840. https://doi.org/10.18632/oncotarget.11068

Metrics: PDF 6967 views | HTML 3287 views | ?

Abstract

Jian Xiao1, Cheng-Ping Hu2, Bi-Xiu He1, Xi Chen2, Xiao-Xiao Lu1, Ming-Xuan Xie1, Wei Li1, Shu-Ya He3, Shao-Jin You4, Qiong Chen1

1Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, Changsha 410008, China

2Department of Respiratory Medicine, Xiangya Hospital of Central South University, Changsha 410008, China

3Department of Biochemistry and Biology, University of South China, Hengyang 421001, China

4Laboratory of Cancer Experimental Therapy, Atlanta Research and Educational Foundation (151F), Atlanta VA Medical Center, Decatur, GA 30033, USA

Correspondence to:

Qiong Chen, email: [email protected]

Keywords: non-small cell lung cancer, NSCLC, PTEN, disease free survival, DFS

Received: June 07, 2016 Accepted: July 20, 2016 Published: August 05, 2016

ABSTRACT

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a known tumor suppressor in non-small cell lung cancer (NSCLC). By performing a systematic review and meta-analysis of the literature, we determined the prognostic value of decreased PTEN expression in patients with NSCLC. We comprehensively and systematically searched through multiple online databases up to May 22, 2016 for NSCLC studies reporting on PTEN expression and patient survival outcome. Several criteria, including the Newcastle-Ottawa Quality Assessment Scale (NOS), were used to discriminate between studies. In total, 23 eligible studies with a total of 2,505 NSCLC patients were included in our meta-analysis. Our results demonstrated that decreased expression of PTEN correlated with poor overall survival in NSCLC patients and was indicative of a poor prognosis for disease-free survival and progression-free survival in patients with NSCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11068

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature

Abstract